S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
S&P 500   0.67 (+1.82%)
DOW   0.67 (+1.82%)
QQQ   265.19 (-1.89%)
AAPL   452.04 (+3.32%)
MSFT   209.19 (+2.86%)
FB   259.89 (+1.47%)
GOOGL   1,507.24 (+1.80%)
AMZN   3,162.24 (+2.65%)
NVDA   457.61 (+5.44%)
CGC   17.25 (+1.77%)
BABA   255.19 (+2.73%)
TSLA   1,554.76 (+13.12%)
GE   6.72 (-0.15%)
MU   48.48 (+1.51%)
AMD   82.61 (+7.45%)
T   30.18 (-0.07%)
F   7.11 (-1.66%)
ACB   9.80 (-2.20%)
GILD   68.84 (+1.09%)
NFLX   475.47 (+1.83%)
DIS   131.79 (+1.00%)
BAC   26.73 (-0.71%)
BA   175.44 (-2.60%)
Log in

NASDAQ:URGNUrogen Pharma Stock Price, Forecast & News

$24.19
-2.23 (-8.44 %)
(As of 08/12/2020 04:00 PM ET)
Add
Compare
Today's Range
$23.70
Now: $24.19
$26.62
50-Day Range
$22.09
MA: $24.44
$29.52
52-Week Range
$13.12
Now: $24.19
$37.08
Volume269,600 shs
Average Volume203,776 shs
Market Capitalization$505.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.59
UroGen Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing novel therapies for urological pathologies. The company's lead product candidates, UGN-101 and UGN-102 are proprietary formulations of the chemotherapy drug mitomycin, a generic drug, which is currently used off-label for urothelial cancer treatment in a water-based formulation as an adjuvant or supplemental in post-surgery therapy. It is developing its product candidates as chemoablation agents, which are designed to remove tumors by non-surgical means, to treat various forms of non-muscle invasive urothelial cancer, including low-grade upper tract urothelial carcinoma, and low-grade bladder cancer. The company has a license agreement with Allergan Pharmaceuticals International Limited for developing and commercializing pharmaceutical products that contain RTGel and clostridial toxins. The company was incorporated in 2004 and is based in New York, New York.
Read More
Urogen Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 3.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.61 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:URGN
CUSIPN/A
Phone646-768-9780

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$20,000.00
Price / Sales25,274.92
Book Value$8.63 per share

Profitability

Net Income$-105,150,000.00

Miscellaneous

Employees70
Market Cap$505.50 million
Next Earnings Date11/10/2020 (Estimated)
OptionableOptionable
$24.19
-2.23 (-8.44 %)
(As of 08/12/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive URGN News and Ratings via Email

Sign-up to receive the latest news and ratings for URGN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Urogen Pharma (NASDAQ:URGN) Frequently Asked Questions

How has Urogen Pharma's stock been impacted by Coronavirus?

Urogen Pharma's stock was trading at $23.86 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, URGN shares have increased by 1.4% and is now trading at $24.19.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Urogen Pharma?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Urogen Pharma in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Urogen Pharma
.

When is Urogen Pharma's next earnings date?

Urogen Pharma is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Urogen Pharma
.

How were Urogen Pharma's earnings last quarter?

Urogen Pharma Ltd (NASDAQ:URGN) issued its quarterly earnings data on Monday, August, 10th. The company reported ($1.44) EPS for the quarter, topping the Zacks' consensus estimate of ($1.59) by $0.15.
View Urogen Pharma's earnings history
.

What price target have analysts set for URGN?

6 equities research analysts have issued 12 month target prices for Urogen Pharma's shares. Their forecasts range from $37.00 to $57.00. On average, they anticipate Urogen Pharma's stock price to reach $45.20 in the next twelve months. This suggests a possible upside of 86.9% from the stock's current price.
View analysts' price targets for Urogen Pharma
.

Has Urogen Pharma been receiving favorable news coverage?

Headlines about URGN stock have trended somewhat negative on Wednesday, according to InfoTrie. InfoTrie scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores closest to five being the most favorable. Urogen Pharma earned a news impact score of -1.2 on InfoTrie's scale. They also gave media stories about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the next several days.
View the latest news about Urogen Pharma
.

Are investors shorting Urogen Pharma?

Urogen Pharma saw a increase in short interest in January. As of January 15th, there was short interest totaling 2,120,000 shares, an increase of 17.8% from the December 31st total of 1,800,000 shares. Based on an average daily volume of 179,400 shares, the days-to-cover ratio is currently 11.8 days. Currently, 12.5% of the shares of the stock are short sold.
View Urogen Pharma's Short Interest
.

Who are some of Urogen Pharma's key competitors?

What other stocks do shareholders of Urogen Pharma own?

Who are Urogen Pharma's key executives?

Urogen Pharma's management team includes the following people:
  • Ms. Elizabeth A. Barrett, Pres, CEO & Director (Age 57)
  • Mr. Peter P. Pfreundschuh, Chief Financial Officer (Age 50)
  • Mr. Stephen Mullennix, Chief Operating Officer
  • Ms. Catherine Bechtold, Director of Corp. Communications & Investor Relations
  • Dr. Sari Prutchi-Sagiv Ph.D., Marketing Director

When did Urogen Pharma IPO?

(URGN) raised $46 million in an initial public offering (IPO) on Thursday, May 4th 2017. The company issued 3,500,000 shares at a price of $12.00-$14.00 per share. Jefferies and Cowen and Company served as the underwriters for the IPO and Raymond James and Oppenheimer were co-managers.

What is Urogen Pharma's stock symbol?

Urogen Pharma trades on the NASDAQ under the ticker symbol "URGN."

Who are Urogen Pharma's major shareholders?

Urogen Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Phoenix Holdings Ltd. (4.29%), Horton Capital Management LLC (1.83%), Goldman Sachs Group Inc. (0.69%), SG Americas Securities LLC (0.63%), Bank of New York Mellon Corp (0.26%) and Meitav Dash Investments Ltd. (0.21%). Company insiders that own Urogen Pharma stock include Elizabeth A Barrett, Mark Schoenberg, Peter P Pfreundschuh and Stephen Mullennix.
View institutional ownership trends for Urogen Pharma
.

Which institutional investors are selling Urogen Pharma stock?

URGN stock was sold by a variety of institutional investors in the last quarter, including California Public Employees Retirement System, and UBS Group AG. Company insiders that have sold Urogen Pharma company stock in the last year include Mark Schoenberg, Peter P Pfreundschuh, and Stephen Mullennix.
View insider buying and selling activity for Urogen Pharma
.

Which institutional investors are buying Urogen Pharma stock?

URGN stock was purchased by a variety of institutional investors in the last quarter, including Horton Capital Management LLC, SG Americas Securities LLC, Goldman Sachs Group Inc., Phoenix Holdings Ltd., Meitav Dash Investments Ltd., Algert Global LLC, Assenagon Asset Management S.A., and Bank of New York Mellon Corp. Company insiders that have bought Urogen Pharma stock in the last two years include Elizabeth A Barrett, and Mark Schoenberg.
View insider buying and selling activity for Urogen Pharma
.

How do I buy shares of Urogen Pharma?

Shares of URGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Urogen Pharma's stock price today?

One share of URGN stock can currently be purchased for approximately $24.19.

How big of a company is Urogen Pharma?

Urogen Pharma has a market capitalization of $505.50 million and generates $20,000.00 in revenue each year. The company earns $-105,150,000.00 in net income (profit) each year or ($5.12) on an earnings per share basis. Urogen Pharma employs 70 workers across the globe.

What is Urogen Pharma's official website?

The official website for Urogen Pharma is www.urogen.com.

How can I contact Urogen Pharma?

Urogen Pharma's mailing address is 400 Alexander Park, Princeton NJ, 08540. The company can be reached via phone at 646-768-9780 or via email at [email protected]

This page was last updated on 8/12/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.